CONMED : J.P. Morgan 2022 CONMED Investor Presentation

J.P. Morgan 40th Annual Healthcare

Conference

Curt R. Hartman

Chair of the Board, President, and Chief Executive Officer

Todd W. Garner

Executive Vice President and Chief Financial Officer

January 10, 2022

Forward-Looking Information

This presentation contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this presentation involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this presentation include, but are not limited to, the risks posed to the Company's business, financial condition, and results of operations by the COVID-19global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability, as well as the risk factors discussed in the Company's Annual Report on Form 10-Kfor the full year ended December 31, 2020 and listed under Forward Looking Statements in the Company's most recently filed Form 10-Q.

Management has disclosed adjusted financial measurements in this presentation that present financial information that is not in accordance with generally accepted accounting principles (GAAP). The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. These measurements are not a substitute for GAAP measurements. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

2

CONMED Vision

Empower healthcare providers worldwide to deliver

exceptional outcomes for patients.

Focus behind the Vision

People, Products, Profitability

3

Objectives for Our Shareholders

▪ Aggregate growthand profitability over the long term to significantly

increase the valuation of the company

▪ Increase our market sharein large and attractive markets

▪ Deliver above-marketrevenue and profitability growthover the long term

4

Orthopedics: Large, Attractive Markets

	Category	Description		Market Size and Competitors	Dollar Value of 1 Market Share Point
	Sports		$4.4 to $4.6 Billion			~$45M
Q3 2021 YTD	Devices for repair of soft	▪	Arthrex	▪	Stryker
Medicine	tissue injuries in joints	▪	DePuy Mitek (J&J)
▪	Smith & Nephew	▪	Zimmer Biomet
	Allograft	Exclusive commercial	$375 to $425 Million
	▪	Allosource			~$4M
	rights to MTF allograft
		▪
	Tissue	tissue	LifeNet
	▪	RTI
US		Surgical drills and saws	$1.4 to $1.6 Billion
Powered	▪				~$15M
36%	DePuy Synthes (J&J)
with related single-use	▪
				Stryker
International	Instruments	accessories	▪	Medtronic (Midas Rex / Xomed)
		▪	Zimmer Biomet
64%
	High-definition surgical	$1.8 to $2.0 Billion
	Surgical	▪	Stryker
	visualization systems to	▪	Olympus	~$19M
	Visualization	enable minimally invasive	▪	Arthrex	▪	Richard Wolf
	▪	Karl Storz	▪
	Smith & Nephew
71%		arthroscopic surgery
						~$83M
Recurring, single-use revenue
	Total	60% to 70% in Surgery Centers in the U.S.	~8% growth for total
	Orthopedics	company based on 2019
							revenue

5